Is Actinium Really Happening?
Journal of Nuclear Medicine · 2023-10 · 64 (10) · 1516-1518
DOI: 10.2967/jnumed.123.265907 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 17.08.2023. Verfasst von Richard Zimmermann. Beteiligte Einrichtung: Chrysalium Consulting, Lalaye, France; MEDraysintell, Louvain-la-Neuve, Belgium; and Oncidium Foundation, Mont-Saint-Guibert, Belgium richard.zimmerm…. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
The most recent survey ([1][1]) related to α-radiotherapy development showed that 27 molecules labeled with 225Ac are presently under development, among which 13 have already reached human test level. The first 225Ac-labeled molecule has entered the clinical phase III stage ([2][2]) and might reach
Autor:innen und Institutionen
- Chrysalium Consulting, Lalaye, France; MEDraysintell, Louvain-la-Neuve, Belgium; and Oncidium Foundation, Mont-Saint-Guibert, Belgium richard.zimmermann@chrysalium.com.
Zitieren
APA
Zimmermann, R. (2023). Is Actinium Really Happening?. Journal of Nuclear Medicine, 64(10), 1516-1518. https://doi.org/10.2967/jnumed.123.265907
Vancouver
Zimmermann R. Is Actinium Really Happening?. Journal of Nuclear Medicine. 2023;64(10):1516-1518. doi:10.2967/jnumed.123.265907
BibTeX
@article{Zimmermann2023,
author = {Zimmermann, Richard},
title = {Is Actinium Really Happening?},
journal = {Journal of Nuclear Medicine},
year = {2023},
volume = {64},
number = {10},
pages = {1516--1518},
doi = {10.2967/jnumed.123.265907}
}
EUVIMED